Abstract:Objective To investigate the clinical efficacy of Nalbuphine combined with Sufentanil for patient-controlled analgesia (PCA) after laparoscopic surgery in hepatobiliary surgery.Methods 120 patients underwent laparoscopic hepatobiliary surgery from January 2018 to January 2020 were selected as the research objects. They were divided into S group, N group and N + S group by random method, with 40 cases in each group. Patients in group S were treated with Sufentanil for postoperative analgesia, patients in group N were treated with Nalbuphine for postoperative analgesia, and patients in group N + S were treated with Nalbuphine combined with Sufentanil for postoperative analgesia. The heart rate (HR), mean arterial pressure (MAP), and visual analogue scales (VAS) of the three groups were recorded. The number of PCA compressions and the occurrence of adverse reactions in the three groups were recorded.Results The MAP and HR of the N + S group were significantly lower than those of the S group at 10 min (T3), 30 min (T4), and 60 min (T4) after the operation, and at T4 and T5, the HR and MAP of the N + S group were significantly lower than those of the N group, the differences were statistically significant (P < 0.05). The VAS scores of patients in the N + S group at 8 h (T7), 12 h (T8), and 24 h (T9) after surgery were significantly lower than those of the S group. The number of PCA compressions in the N + S group was significantly less than that of the S group, and the differences were statistically significant (P < 0.05). The number of adverse reactions in the N + S group was significantly lower than that of the N and S groups, and the difference was statistically significant (P < 0.05).Conclusion The combined application of Nalbuphine and Sufentanil in laparoscopic postoperative analgesia in hepatobiliary surgery can achieve good analgesic effects and high drug safety, and it is worthy of popularization.